ONTOLOGY REPORT - ANNOTATIONS
| Term: | tetrahydroxyflavone |
|
| Accession: | CHEBI:38684
|
browse the term
|
| Synonyms: | related_synonym: | tetrahydroxyflavones |
| | alt_id: | CHEBI:26924; CHEBI:27117 |
|
|
4',5,7-trihydroxy-3'-methoxyflavone
|
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
decreases activity |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
multiple interactions |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
| G |
Mtnr1a |
melatonin receptor 1A |
|
affects binding |
ISO |
16 |
50,439,407 |
50,458,585 |
RGD:6480464 |
CTD |
| G |
Mtnr1b |
melatonin receptor 1B |
|
affects binding |
ISO |
8 |
12,625,154 |
12,639,670 |
RGD:6480464 |
CTD |
| G |
Nqo2 |
NAD(P)H dehydrogenase, quinone 2 |
|
multiple interactions |
ISO |
17 |
37,255,630 |
37,283,753 |
RGD:6480464 |
CTD |
6-hydroxyluteolin
|
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases chemical synthesis |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
increases chemical synthesis |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
multiple interactions |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
diosmetin
|
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
decreases activity |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
decreases activity |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
decreases activity |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
|
multiple interactions |
ISO |
12 |
17,164,384 |
17,204,589 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Slc16a1 |
solute carrier family 16, member 1 (monocarboxylic acid transporter 1) |
|
multiple interactions |
EXP |
2 |
199,860,341 |
199,879,856 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
fisetin
|
| G |
Afp |
alpha-fetoprotein |
|
affects binding |
EXP |
14 |
19,092,563 |
19,110,728 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
decreases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Bak1 |
BCL2-antagonist/killer 1 |
|
multiple interactions |
ISO |
20 |
5,255,954 |
5,264,593 |
RGD:6480464 |
CTD |
| G |
Bid |
BH3 interacting domain death agonist |
|
multiple interactions |
ISO |
4 |
157,296,383 |
157,318,481 |
RGD:6480464 |
CTD |
| G |
Bid |
BH3 interacting domain death agonist |
|
increases cleavage |
ISO |
4 |
157,296,383 |
157,318,481 |
RGD:6480464 |
CTD |
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp7 |
caspase 7 |
|
multiple interactions |
ISO |
1 |
262,689,300 |
262,721,591 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
multiple interactions |
ISO |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
increases activity |
ISO |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
multiple interactions |
ISO |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Ccnb1 |
cyclin B1 |
|
multiple interactions |
ISO |
2 |
31,574,600 |
31,581,784 |
RGD:6480464 |
CTD |
| G |
Ccnb1 |
cyclin B1 |
|
decreases expression |
ISO |
2 |
31,574,600 |
31,581,784 |
RGD:6480464 |
CTD |
| G |
Cd40 |
CD40 molecule, TNF receptor superfamily member 5 |
|
multiple interactions |
ISO |
3 |
156,092,602 |
156,107,427 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
multiple interactions |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Comt |
catechol-O-methyltransferase |
|
multiple interactions |
ISO |
11 |
84,561,591 |
84,581,713 |
RGD:6480464 |
CTD |
| G |
Dio2 |
deiodinase, iodothyronine, type II |
|
increases activity |
ISO |
6 |
114,307,758 |
114,317,563 |
RGD:6480464 |
CTD |
| G |
Dnmt1 |
DNA (cytosine-5-)-methyltransferase 1 |
|
multiple interactions |
ISO |
8 |
19,926,995 |
19,973,256 |
RGD:6480464 |
CTD |
| G |
Faslg |
Fas ligand (TNF superfamily, member 6) |
|
multiple interactions |
ISO |
13 |
77,472,950 |
77,480,210 |
RGD:6480464 |
CTD |
| G |
Faslg |
Fas ligand (TNF superfamily, member 6) |
|
increases expression |
ISO |
13 |
77,472,950 |
77,480,210 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
increases expression |
ISO |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Il13 |
interleukin 13 |
|
multiple interactions |
ISO |
10 |
39,093,512 |
39,096,069 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il4 |
interleukin 4 |
|
multiple interactions |
ISO |
10 |
39,074,582 |
39,080,134 |
RGD:6480464 |
CTD |
| G |
Il4 |
interleukin 4 |
|
decreases expression |
ISO |
10 |
39,074,582 |
39,080,134 |
RGD:6480464 |
CTD |
| G |
Il5 |
interleukin 5 |
|
multiple interactions |
ISO |
10 |
39,177,786 |
39,180,657 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases phosphorylation |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases phosphorylation |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
multiple interactions |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Nfatc2 |
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 |
|
multiple interactions |
ISO |
3 |
159,656,032 |
159,773,643 |
RGD:6480464 |
CTD |
| G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
|
increases expression |
ISO |
3 |
58,366,693 |
58,394,116 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
decreases activity |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Slc16a1 |
solute carrier family 16, member 1 (monocarboxylic acid transporter 1) |
|
multiple interactions |
EXP |
2 |
199,860,341 |
199,879,856 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases expression |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
affects localization |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Ugt1a1 |
UDP glucuronosyltransferase 1 family, polypeptide A1 |
|
increases glucuronidation |
ISO |
9 |
87,091,241 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt1a8 |
UDP glycosyltransferase 1 family, polypeptide A8 |
|
increases glucuronidation |
ISO |
9 |
87,017,029 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt1a9 |
UDP glucuronosyltransferase 1 family, polypeptide A9 |
|
increases glucuronidation |
ISO |
9 |
86,986,915 |
87,098,362 |
RGD:6480464 |
CTD |
isoorientin
|
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
multiple interactions |
EXP |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Potef |
POTE ankyrin domain family, member F |
|
multiple interactions |
EXP |
18 |
24,420,779 |
24,422,284 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
multiple interactions |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
isorhamnetin
|
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases transport |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
decreases activity |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
decreases expression |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
affects binding |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
affects binding |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
|
multiple interactions |
ISO |
4 |
6,158,847 |
6,179,441 |
RGD:6480464 |
CTD |
| G |
Olr1 |
oxidized low density lipoprotein (lectin-like) receptor 1 |
|
multiple interactions |
ISO |
4 |
166,747,228 |
166,769,340 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Tff1 |
trefoil factor 1 |
|
increases expression |
ISO |
20 |
9,526,674 |
9,530,534 |
RGD:6480464 |
CTD |
kaempferol
|
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases transport |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
decreases activity |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
affects activity |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Afp |
alpha-fetoprotein |
|
affects binding |
EXP |
14 |
19,092,563 |
19,110,728 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
affects binding |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
increases activity |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Aip |
aryl-hydrocarbon receptor-interacting protein |
|
multiple interactions |
ISO |
1 |
206,697,248 |
206,704,457 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Alox12 |
arachidonate 12-lipoxygenase |
|
decreases activity |
ISO |
10 |
57,080,603 |
57,092,874 |
RGD:6480464 |
CTD |
| G |
Alox12 |
arachidonate 12-lipoxygenase |
|
multiple interactions |
ISO |
10 |
57,080,603 |
57,092,874 |
RGD:6480464 |
CTD |
| G |
Apoe |
apolipoprotein E |
|
multiple interactions |
ISO |
1 |
79,003,634 |
79,006,387 |
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
multiple interactions |
EXP |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
|
multiple interactions |
ISO |
2 |
190,333,978 |
190,391,015 |
RGD:6480464 |
CTD |
| G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
|
multiple interactions |
ISO |
2 |
190,333,978 |
190,391,015 |
RGD:6480464 |
CTD |
| G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
|
multiple interactions |
ISO |
2 |
190,333,978 |
190,391,015 |
RGD:6480464 |
CTD |
| G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
|
multiple interactions |
ISO |
2 |
190,333,978 |
190,391,015 |
RGD:6480464 |
CTD |
| G |
Atm |
ataxia telangiectasia mutated |
|
multiple interactions |
ISO |
8 |
56,894,746 |
56,996,565 |
RGD:6480464 |
CTD |
| G |
Atm |
ataxia telangiectasia mutated |
|
increases phosphorylation |
ISO |
8 |
56,894,746 |
56,996,565 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
increases expression |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
multiple interactions |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bbc3 |
Bcl-2 binding component 3 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bbc3 |
Bcl-2 binding component 3 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
multiple interactions |
ISO |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Calcr |
calcitonin receptor |
|
multiple interactions |
ISO |
4 |
28,486,176 |
28,561,296 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases cleavage |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases cleavage |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases cleavage |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases cleavage |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases cleavage |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl5 |
chemokine (C-C motif) ligand 5 |
|
multiple interactions |
ISO |
10 |
71,605,791 |
71,610,330 |
RGD:6480464 |
CTD |
| G |
Ccnb1 |
cyclin B1 |
|
decreases expression |
ISO |
2 |
31,574,600 |
31,581,784 |
RGD:6480464 |
CTD |
| G |
Ccnb1 |
cyclin B1 |
|
decreases expression |
ISO |
2 |
31,574,600 |
31,581,784 |
RGD:6480464 |
CTD |
| G |
Cd44 |
Cd44 molecule |
|
multiple interactions |
ISO |
3 |
88,022,962 |
88,110,352 |
RGD:6480464 |
CTD |
| G |
Cdk1 |
cyclin-dependent kinase 1 |
|
multiple interactions |
ISO |
20 |
20,018,044 |
20,044,030 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) |
|
decreases expression |
ISO |
5 |
131,012,524 |
131,017,679 |
RGD:6480464 |
CTD |
| G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
|
affects localization |
ISO |
4 |
43,874,852 |
44,041,870 |
RGD:6480464 |
CTD |
| G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
|
decreases phosphorylation |
ISO |
1 |
249,122,845 |
249,158,369 |
RGD:6480464 |
CTD |
| G |
Crp |
C-reactive protein, pentraxin-related |
|
decreases expression |
ISO |
13 |
88,702,243 |
88,703,153 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
increases secretion |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Cycs |
cytochrome c, somatic |
|
multiple interactions |
ISO |
4 |
78,825,878 |
78,827,978 |
RGD:6480464 |
CTD |
| G |
Cycs |
cytochrome c, somatic |
|
affects localization |
ISO |
4 |
78,825,878 |
78,827,978 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases expression |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
decreases activity |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
decreases activity |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
decreases activity |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
decreases activity |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases activity |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
decreases activity |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
increases expression |
ISO |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
multiple interactions |
EXP |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
increases expression |
EXP |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
decreases activity |
ISO |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
decreases activity |
ISO |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
decreases expression |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
decreases activity |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
decreases activity |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
multiple interactions |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
multiple interactions |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
multiple interactions |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases expression |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
decreases activity |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
decreases activity |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Dio2 |
deiodinase, iodothyronine, type II |
|
increases activity |
ISO |
6 |
114,307,758 |
114,317,563 |
RGD:6480464 |
CTD |
| G |
Dio2 |
deiodinase, iodothyronine, type II |
|
multiple interactions |
ISO |
6 |
114,307,758 |
114,317,563 |
RGD:6480464 |
CTD |
| G |
Dio2 |
deiodinase, iodothyronine, type II |
|
increases expression |
ISO |
6 |
114,307,758 |
114,317,563 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
multiple interactions |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
multiple interactions |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
affects binding |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
multiple interactions |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
increases activity |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
increases expression |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
affects binding |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
multiple interactions |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
affects binding |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
affects binding |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
affects binding |
EXP |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
multiple interactions |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
multiple interactions |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
multiple interactions |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
multiple interactions |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
multiple interactions |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
affects binding |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
increases activity |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
multiple interactions |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
increases activity |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
affects binding |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
affects binding |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
affects binding |
EXP |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
affects binding |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Fbp1 |
fructose-1,6-bisphosphatase 1 |
|
decreases expression |
ISO |
17 |
7,795,717 |
7,818,041 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
|
increases expression |
ISO |
7 |
10,289,073 |
10,291,102 |
RGD:6480464 |
CTD |
| G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
|
increases expression |
ISO |
8 |
82,724,429 |
82,762,848 |
RGD:6480464 |
CTD |
| G |
Gsta1 |
glutathione S-transferase alpha 1 |
|
increases expression |
ISO |
9 |
20,051,501 |
20,068,146 |
RGD:6480464 |
CTD |
| G |
Gstp1 |
glutathione S-transferase pi 1 |
|
decreases activity |
ISO |
1 |
206,627,398 |
206,629,866 |
RGD:6480464 |
CTD |
| G |
H2afx |
H2A histone family, member X |
|
increases phosphorylation |
ISO |
8 |
47,312,609 |
47,313,938 |
RGD:6480464 |
CTD |
| G |
Hbb |
hemoglobin, beta |
|
multiple interactions |
ISO |
1 |
161,618,782 |
161,620,193 |
RGD:6480464 |
CTD |
| G |
Hgf |
hepatocyte growth factor |
|
multiple interactions |
ISO |
4 |
14,864,357 |
14,932,513 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
ISO |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
increases expression |
ISO |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
increases expression |
EXP |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
increases expression |
EXP |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
increases expression |
EXP |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
multiple interactions |
ISO |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il4 |
interleukin 4 |
|
multiple interactions |
ISO |
10 |
39,074,582 |
39,080,134 |
RGD:6480464 |
CTD |
| G |
Il5 |
interleukin 5 |
|
multiple interactions |
ISO |
10 |
39,177,786 |
39,180,657 |
RGD:6480464 |
CTD |
| G |
Il5 |
interleukin 5 |
|
multiple interactions |
ISO |
10 |
39,177,786 |
39,180,657 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Ins1 |
insulin 1 |
|
multiple interactions |
ISO |
1 |
258,001,134 |
258,001,688 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
multiple interactions |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Kmt2a |
lysine (K)-specific methyltransferase 2A |
|
increases mutagenesis |
ISO |
8 |
47,759,175 |
47,834,586 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases phosphorylation |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases activity |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases phosphorylation |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases activity |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mt2A |
metallothionein 2A |
|
increases expression |
ISO |
19 |
11,267,811 |
11,268,585 |
RGD:6480464 |
CTD |
| G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ncoa3 |
nuclear receptor coactivator 3 |
|
multiple interactions |
ISO |
3 |
157,168,492 |
157,196,566 |
RGD:6480464 |
CTD |
| G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
|
increases expression |
ISO |
3 |
58,366,693 |
58,394,116 |
RGD:6480464 |
CTD |
| G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
|
multiple interactions |
ISO |
3 |
58,366,693 |
58,394,116 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
decreases phosphorylation |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
decreases expression |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
|
increases activity |
ISO |
11 |
64,239,918 |
64,276,702 |
RGD:6480464 |
CTD |
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
increases activity |
ISO |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
EXP |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Pgr |
progesterone receptor |
|
affects binding |
ISO |
8 |
5,784,717 |
5,845,901 |
RGD:6480464 |
CTD |
| G |
Pgr |
progesterone receptor |
|
multiple interactions |
ISO |
8 |
5,784,717 |
5,845,901 |
RGD:6480464 |
CTD |
| G |
Pgr |
progesterone receptor |
|
multiple interactions |
ISO |
8 |
5,784,717 |
5,845,901 |
RGD:6480464 |
CTD |
| G |
Pgr |
progesterone receptor |
|
increases expression |
ISO |
8 |
5,784,717 |
5,845,901 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Ppargc1a |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
increases expression |
ISO |
14 |
64,278,115 |
64,370,912 |
RGD:6480464 |
CTD |
| G |
Psca |
prostate stem cell antigen |
|
decreases expression |
ISO |
7 |
112,823,862 |
112,835,190 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rpa3 |
replication protein A3 |
|
multiple interactions |
ISO |
4 |
33,304,334 |
33,307,365 |
RGD:6480464 |
CTD |
| G |
Sfn |
stratifin |
|
increases expression |
ISO |
5 |
151,475,395 |
151,479,996 |
RGD:6480464 |
CTD |
| G |
Slc16a1 |
solute carrier family 16, member 1 (monocarboxylic acid transporter 1) |
|
multiple interactions |
EXP |
2 |
199,860,341 |
199,879,856 |
RGD:6480464 |
CTD |
| G |
Slc2a1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
decreases activity |
ISO |
5 |
139,690,801 |
139,719,021 |
RGD:6480464 |
CTD |
| G |
Slc2a1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
multiple interactions |
ISO |
5 |
139,690,801 |
139,719,021 |
RGD:6480464 |
CTD |
| G |
Spp1 |
secreted phosphoprotein 1 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Stat1 |
signal transducer and activator of transcription 1 |
|
multiple interactions |
ISO |
9 |
46,455,635 |
46,497,560 |
RGD:6480464 |
CTD |
| G |
Stat2 |
signal transducer and activator of transcription 2 |
|
multiple interactions |
ISO |
7 |
1,564,385 |
1,580,652 |
RGD:6480464 |
CTD |
| G |
Tfam |
transcription factor A, mitochondrial |
|
increases expression |
ISO |
20 |
18,100,629 |
18,112,682 |
RGD:6480464 |
CTD |
| G |
Tff1 |
trefoil factor 1 |
|
increases expression |
ISO |
20 |
9,526,674 |
9,530,534 |
RGD:6480464 |
CTD |
| G |
Tff1 |
trefoil factor 1 |
|
increases expression |
ISO |
20 |
9,526,674 |
9,530,534 |
RGD:6480464 |
CTD |
| G |
Tff1 |
trefoil factor 1 |
|
multiple interactions |
ISO |
20 |
9,526,674 |
9,530,534 |
RGD:6480464 |
CTD |
| G |
Tgfa |
transforming growth factor alpha |
|
multiple interactions |
ISO |
4 |
120,355,649 |
120,437,772 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnfrsf11a |
tumor necrosis factor receptor superfamily, member 11a, NFKB activator |
|
multiple interactions |
ISO |
13 |
11,958,002 |
12,014,371 |
RGD:6480464 |
CTD |
| G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
|
multiple interactions |
ISO |
15 |
59,397,837 |
59,428,014 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases expression |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases phosphorylation |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
affects response to substance |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
EXP |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp63 |
tumor protein p63 |
|
increases expression |
ISO |
11 |
76,900,622 |
77,200,251 |
RGD:6480464 |
CTD |
| G |
Tp63 |
tumor protein p63 |
|
increases expression |
ISO |
11 |
76,900,622 |
77,200,251 |
RGD:6480464 |
CTD |
| G |
Tp73 |
tumor protein p73 |
|
increases expression |
ISO |
5 |
170,848,979 |
171,078,739 |
RGD:6480464 |
CTD |
| G |
Tp73 |
tumor protein p73 |
|
increases expression |
ISO |
5 |
170,848,979 |
171,078,739 |
RGD:6480464 |
CTD |
| G |
Ucp3 |
uncoupling protein 3 (mitochondrial, proton carrier) |
|
increases expression |
ISO |
1 |
157,896,001 |
157,909,608 |
RGD:6480464 |
CTD |
| G |
Ugt1a1 |
UDP glucuronosyltransferase 1 family, polypeptide A1 |
|
increases glucuronidation |
ISO |
9 |
87,091,241 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
|
affects glucuronidation |
ISO |
9 |
87,081,132 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
|
increases glucuronidation |
ISO |
9 |
87,081,132 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt1a8 |
UDP glycosyltransferase 1 family, polypeptide A8 |
|
increases glucuronidation |
ISO |
9 |
87,017,029 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt1a9 |
UDP glucuronosyltransferase 1 family, polypeptide A9 |
|
increases glucuronidation |
ISO |
9 |
86,986,915 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Utrn |
utrophin |
|
increases expression |
ISO |
1 |
7,099,840 |
7,614,980 |
RGD:6480464 |
CTD |
| G |
Wisp2 |
WNT1 inducible signaling pathway protein 2 |
|
increases expression |
ISO |
3 |
154,748,977 |
154,760,324 |
RGD:6480464 |
CTD |
| G |
Wisp2 |
WNT1 inducible signaling pathway protein 2 |
|
multiple interactions |
ISO |
3 |
154,748,977 |
154,760,324 |
RGD:6480464 |
CTD |
kaempferol 3-O-beta-D-galactoside
|
| G |
Pla2g2a |
phospholipase A2, group IIA (platelets, synovial fluid) |
|
affects activity |
ISO |
5 |
157,654,786 |
157,657,360 |
RGD:6480464 |
CTD |
kaempferol 3-O-glucoside
|
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl3 |
chemokine (C-C motif) ligand 3 |
|
multiple interactions |
ISO |
10 |
71,744,559 |
71,746,109 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
luteolin
|
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
decreases activity |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcg2 |
ATP-binding cassette, subfamily G (WHITE), member 2 |
|
affects activity |
ISO |
4 |
87,502,584 |
87,560,017 |
RGD:6480464 |
CTD |
| G |
Ager |
advanced glycosylation end product-specific receptor |
|
multiple interactions |
ISO |
20 |
4,250,613 |
4,253,540 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
decreases expression |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
increases expression |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
decreases expression |
ISO |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Birc2 |
baculoviral IAP repeat-containing 2 |
|
multiple interactions |
ISO |
8 |
4,649,559 |
4,667,733 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases cleavage |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases cleavage |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp7 |
caspase 7 |
|
increases activity |
ISO |
1 |
262,689,300 |
262,721,591 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
multiple interactions |
ISO |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
multiple interactions |
ISO |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases cleavage |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases cleavage |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
affects activity |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Ccna2 |
cyclin A2 |
|
decreases expression |
ISO |
2 |
123,062,752 |
123,069,085 |
RGD:6480464 |
CTD |
| G |
Ccnb1 |
cyclin B1 |
|
decreases expression |
ISO |
2 |
31,574,600 |
31,581,784 |
RGD:6480464 |
CTD |
| G |
Ccnb1 |
cyclin B1 |
|
decreases expression |
ISO |
2 |
31,574,600 |
31,581,784 |
RGD:6480464 |
CTD |
| G |
Ccnb1 |
cyclin B1 |
|
decreases expression |
ISO |
2 |
31,574,600 |
31,581,784 |
RGD:6480464 |
CTD |
| G |
Cd40 |
CD40 molecule, TNF receptor superfamily member 5 |
|
multiple interactions |
ISO |
3 |
156,092,602 |
156,107,427 |
RGD:6480464 |
CTD |
| G |
Cd74 |
Cd74 molecule, major histocompatibility complex, class II invariant chain |
|
decreases expression |
ISO |
18 |
56,756,511 |
56,765,711 |
RGD:6480464 |
CTD |
| G |
Cdk1 |
cyclin-dependent kinase 1 |
|
decreases expression |
ISO |
20 |
20,018,044 |
20,044,030 |
RGD:6480464 |
CTD |
| G |
Cdk2 |
cyclin dependent kinase 2 |
|
decreases activity |
ISO |
7 |
2,000,196 |
2,007,682 |
RGD:6480464 |
CTD |
| G |
Cdk2 |
cyclin dependent kinase 2 |
|
decreases expression |
ISO |
7 |
2,000,196 |
2,007,682 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
increases expression |
ISO |
4 |
171,841,705 |
171,846,506 |
RGD:6480464 |
CTD |
| G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) |
|
decreases expression |
ISO |
5 |
131,012,524 |
131,017,679 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
decreases expression |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
EXP |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Cxcl10 |
chemokine (C-X-C motif) ligand 10 |
|
multiple interactions |
ISO |
14 |
17,265,986 |
17,268,183 |
RGD:6480464 |
CTD |
| G |
Cxcl9 |
chemokine (C-X-C motif) ligand 9 |
|
multiple interactions |
ISO |
14 |
17,284,085 |
17,288,996 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
decreases activity |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases expression |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases expression |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
decreases activity |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
|
multiple interactions |
ISO |
12 |
17,164,384 |
17,204,589 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
decreases expression |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egr1 |
early growth response 1 |
|
increases expression |
ISO |
18 |
27,343,919 |
27,346,117 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
affects binding |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
multiple interactions |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
increases activity |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
affects binding |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Fbp1 |
fructose-1,6-bisphosphatase 1 |
|
decreases expression |
ISO |
17 |
7,795,717 |
7,818,041 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
decreases activity |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fosb |
FBJ osteosarcoma oncogene B |
|
decreases activity |
ISO |
1 |
78,668,497 |
78,673,330 |
RGD:6480464 |
CTD |
| G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
|
increases expression |
ISO |
7 |
10,289,073 |
10,291,102 |
RGD:6480464 |
CTD |
| G |
Gfap |
glial fibrillary acidic protein |
|
multiple interactions |
ISO |
10 |
92,059,881 |
92,068,555 |
RGD:6480464 |
CTD |
| G |
Gpx1 |
glutathione peroxidase 1 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
ISO |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
multiple interactions |
ISO |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
multiple interactions |
ISO |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Ifnb1 |
interferon beta 1, fibroblast |
|
multiple interactions |
ISO |
5 |
107,837,628 |
107,838,182 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
increases expression |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
EXP |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
multiple interactions |
ISO |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il12b |
interleukin 12B |
|
multiple interactions |
ISO |
10 |
29,558,955 |
29,568,331 |
RGD:6480464 |
CTD |
| G |
Il13 |
interleukin 13 |
|
multiple interactions |
EXP |
10 |
39,093,512 |
39,096,069 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il27 |
interleukin 27 |
|
multiple interactions |
ISO |
1 |
185,730,394 |
185,735,604 |
RGD:6480464 |
CTD |
| G |
Il3 |
interleukin 3 |
|
multiple interactions |
EXP |
10 |
39,684,691 |
39,687,041 |
RGD:6480464 |
CTD |
| G |
Il4 |
interleukin 4 |
|
multiple interactions |
ISO |
10 |
39,074,582 |
39,080,134 |
RGD:6480464 |
CTD |
| G |
Il4 |
interleukin 4 |
|
decreases expression |
ISO |
10 |
39,074,582 |
39,080,134 |
RGD:6480464 |
CTD |
| G |
Il4 |
interleukin 4 |
|
decreases expression |
ISO |
10 |
39,074,582 |
39,080,134 |
RGD:6480464 |
CTD |
| G |
Il4 |
interleukin 4 |
|
multiple interactions |
EXP |
10 |
39,074,582 |
39,080,134 |
RGD:6480464 |
CTD |
| G |
Il5 |
interleukin 5 |
|
decreases expression |
ISO |
10 |
39,177,786 |
39,180,657 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Ins1 |
insulin 1 |
|
multiple interactions |
EXP |
1 |
258,001,134 |
258,001,688 |
RGD:6480464 |
CTD |
| G |
Irf3 |
interferon regulatory factor 3 |
|
multiple interactions |
ISO |
1 |
95,470,284 |
95,475,078 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
multiple interactions |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
multiple interactions |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
multiple interactions |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
decreases phosphorylation |
EXP |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Junb |
jun B proto-oncogene |
|
decreases activity |
ISO |
19 |
24,831,536 |
24,833,320 |
RGD:6480464 |
CTD |
| G |
Jund |
jun D proto-oncogene |
|
decreases activity |
ISO |
16 |
19,239,694 |
19,241,529 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases activity |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk10 |
mitogen activated protein kinase 10 |
|
increases phosphorylation |
ISO |
14 |
7,719,595 |
8,010,694 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases activity |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
increases phosphorylation |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk9 |
mitogen-activated protein kinase 9 |
|
increases phosphorylation |
ISO |
10 |
35,353,486 |
35,384,319 |
RGD:6480464 |
CTD |
| G |
Mmp1 |
matrix metallopeptidase 1 (interstitial collagenase) |
|
decreases expression |
ISO |
8 |
4,333,773 |
4,354,284 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
multiple interactions |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
decreases secretion |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
multiple interactions |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
|
multiple interactions |
EXP |
3 |
58,366,693 |
58,394,116 |
RGD:6480464 |
CTD |
| G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
|
increases activity |
EXP |
3 |
58,366,693 |
58,394,116 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions |
ISO |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions |
EXP |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
EXP |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbib |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta |
|
multiple interactions |
ISO |
1 |
83,865,440 |
83,873,010 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
|
decreases expression |
ISO |
10 |
87,541,246 |
87,548,186 |
RGD:6480464 |
CTD |
| G |
Plk1 |
polo-like kinase 1 |
|
decreases expression |
ISO |
1 |
181,002,811 |
181,012,741 |
RGD:6480464 |
CTD |
| G |
Potef |
POTE ankyrin domain family, member F |
|
multiple interactions |
ISO |
18 |
24,420,779 |
24,422,284 |
RGD:6480464 |
CTD |
| G |
Psca |
prostate stem cell antigen |
|
decreases expression |
ISO |
7 |
112,823,862 |
112,835,190 |
RGD:6480464 |
CTD |
| G |
Psca |
prostate stem cell antigen |
|
decreases expression |
ISO |
7 |
112,823,862 |
112,835,190 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptk2 |
protein tyrosine kinase 2 |
|
multiple interactions |
ISO |
7 |
110,933,298 |
111,084,554 |
RGD:6480464 |
CTD |
| G |
Ptk2 |
protein tyrosine kinase 2 |
|
decreases phosphorylation |
ISO |
7 |
110,933,298 |
111,084,554 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Sele |
selectin E |
|
multiple interactions |
ISO |
13 |
79,813,455 |
79,822,845 |
RGD:6480464 |
CTD |
| G |
Sfn |
stratifin |
|
increases expression |
ISO |
5 |
151,475,395 |
151,479,996 |
RGD:6480464 |
CTD |
| G |
Slc16a1 |
solute carrier family 16, member 1 (monocarboxylic acid transporter 1) |
|
multiple interactions |
EXP |
2 |
199,860,341 |
199,879,856 |
RGD:6480464 |
CTD |
| G |
Sod1 |
superoxide dismutase 1, soluble |
|
affects activity |
ISO |
11 |
29,810,766 |
29,816,342 |
RGD:6480464 |
CTD |
| G |
Sod1 |
superoxide dismutase 1, soluble |
|
multiple interactions |
ISO |
11 |
29,810,766 |
29,816,342 |
RGD:6480464 |
CTD |
| G |
Tbk1 |
TANK-binding kinase 1 |
|
decreases activity |
ISO |
7 |
60,863,099 |
60,896,131 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
|
multiple interactions |
ISO |
2 |
113,204,303 |
113,221,550 |
RGD:6480464 |
CTD |
| G |
Top1 |
topoisomerase (DNA) I |
|
multiple interactions |
EXP |
3 |
151,428,931 |
151,512,884 |
RGD:6480464 |
CTD |
| G |
Tp63 |
tumor protein p63 |
|
increases expression |
ISO |
11 |
76,900,622 |
77,200,251 |
RGD:6480464 |
CTD |
| G |
Tp63 |
tumor protein p63 |
|
increases expression |
ISO |
11 |
76,900,622 |
77,200,251 |
RGD:6480464 |
CTD |
| G |
Tp73 |
tumor protein p73 |
|
increases expression |
ISO |
5 |
170,848,979 |
171,078,739 |
RGD:6480464 |
CTD |
| G |
Tp73 |
tumor protein p73 |
|
increases expression |
ISO |
5 |
170,848,979 |
171,078,739 |
RGD:6480464 |
CTD |
| G |
Tyr |
tyrosinase |
|
increases expression |
ISO |
1 |
143,641,257 |
143,746,315 |
RGD:6480464 |
CTD |
| G |
Ugt1a1 |
UDP glucuronosyltransferase 1 family, polypeptide A1 |
|
multiple interactions |
ISO |
9 |
87,091,241 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
|
affects glucuronidation |
ISO |
9 |
87,081,132 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
|
increases glucuronidation |
ISO |
9 |
87,081,132 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Vav3 |
vav 3 guanine nucleotide exchange factor |
|
decreases expression |
ISO |
2 |
204,982,222 |
205,326,505 |
RGD:6480464 |
CTD |
| G |
Vcam1 |
vascular cell adhesion molecule 1 |
|
multiple interactions |
ISO |
2 |
212,277,654 |
212,297,376 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
decreases expression |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Wisp2 |
WNT1 inducible signaling pathway protein 2 |
|
decreases expression |
ISO |
3 |
154,748,977 |
154,760,324 |
RGD:6480464 |
CTD |
| G |
Xiap |
X-linked inhibitor of apoptosis |
|
multiple interactions |
ISO |
X |
3,011,520 |
3,047,798 |
RGD:6480464 |
CTD |
luteolin 7-O-beta-D-glucoside
|
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
quercetin 3-O-beta-D-glucoside
|
| G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
|
multiple interactions |
ISO |
1 |
41,922,020 |
41,940,074 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
EXP |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl5 |
chemokine (C-C motif) ligand 5 |
|
multiple interactions |
EXP |
10 |
71,605,791 |
71,610,330 |
RGD:6480464 |
CTD |
| G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) |
|
multiple interactions |
EXP |
5 |
108,939,669 |
108,945,293 |
RGD:6480464 |
CTD |
| G |
Cxcl2 |
chemokine (C-X-C motif) ligand 2 |
|
multiple interactions |
EXP |
14 |
18,677,129 |
18,679,175 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
EXP |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
decreases activity |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
multiple interactions |
EXP |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
decreases activity |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
| G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
|
multiple interactions |
EXP |
1 |
81,345,425 |
81,359,415 |
RGD:6480464 |
CTD |
| G |
Cyp51 |
cytochrome P450, family 51 |
|
multiple interactions |
ISO |
4 |
26,752,677 |
26,771,131 |
RGD:6480464 |
CTD |
| G |
Dhcr7 |
7-dehydrocholesterol reductase |
|
multiple interactions |
ISO |
1 |
204,245,562 |
204,258,913 |
RGD:6480464 |
CTD |
| G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
|
multiple interactions |
ISO |
15 |
42,425,336 |
42,453,390 |
RGD:6480464 |
CTD |
| G |
Fdps |
farnesyl diphosphate synthase |
|
multiple interactions |
ISO |
2 |
181,138,474 |
181,177,903 |
RGD:6480464 |
CTD |
| G |
Gpx2 |
glutathione peroxidase 2 |
|
multiple interactions |
EXP |
6 |
99,372,418 |
99,376,230 |
RGD:6480464 |
CTD |
| G |
Gsta5 |
glutathione S-transferase alpha 5 |
|
multiple interactions |
EXP |
8 |
83,202,554 |
83,211,997 |
RGD:6480464 |
CTD |
| G |
Gsta5 |
glutathione S-transferase alpha 5 |
|
multiple interactions |
EXP |
8 |
83,202,554 |
83,211,997 |
RGD:6480464 |
CTD |
| G |
Gstm1 |
glutathione S-transferase mu 1 |
|
multiple interactions |
EXP |
2 |
203,575,444 |
203,580,821 |
RGD:6480464 |
CTD |
| G |
Gstm1 |
glutathione S-transferase mu 1 |
|
multiple interactions |
EXP |
2 |
203,575,444 |
203,580,821 |
RGD:6480464 |
CTD |
| G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
|
multiple interactions |
ISO |
2 |
27,127,504 |
27,149,580 |
RGD:6480464 |
CTD |
| G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) |
|
multiple interactions |
ISO |
2 |
51,737,090 |
51,754,583 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
EXP |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Il1a |
interleukin 1 alpha |
|
multiple interactions |
EXP |
3 |
116,913,612 |
116,924,114 |
RGD:6480464 |
CTD |
| G |
Insig1 |
insulin induced gene 1 |
|
multiple interactions |
ISO |
4 |
2,577,468 |
2,585,682 |
RGD:6480464 |
CTD |
| G |
Ldlr |
low density lipoprotein receptor |
|
multiple interactions |
ISO |
8 |
20,824,040 |
20,846,920 |
RGD:6480464 |
CTD |
| G |
Me1 |
malic enzyme 1, NADP(+)-dependent, cytosolic |
|
multiple interactions |
EXP |
8 |
91,839,845 |
91,955,917 |
RGD:6480464 |
CTD |
| G |
Mmp2 |
matrix metallopeptidase 2 |
|
multiple interactions |
ISO |
19 |
15,246,036 |
15,275,061 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
multiple interactions |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
EXP |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
|
multiple interactions |
EXP |
19 |
37,251,147 |
37,266,040 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Sc5d |
sterol-C5-desaturase |
|
multiple interactions |
ISO |
8 |
45,229,976 |
45,238,924 |
RGD:6480464 |
CTD |
| G |
Serpine1 |
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 |
|
multiple interactions |
EXP |
12 |
20,931,996 |
20,942,374 |
RGD:6480464 |
CTD |
| G |
Sqle |
squalene epoxidase |
|
multiple interactions |
ISO |
7 |
96,096,897 |
96,111,772 |
RGD:6480464 |
CTD |
| G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
|
multiple interactions |
ISO |
7 |
120,522,511 |
120,580,212 |
RGD:6480464 |
CTD |
| G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
|
increases expression |
ISO |
X |
12,542,496 |
12,547,094 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
|
multiple interactions |
EXP |
4 |
162,172,563 |
162,185,252 |
RGD:6480464 |
CTD |
| G |
Tradd |
TNFRSF1A-associated via death domain |
|
multiple interactions |
EXP |
19 |
35,073,150 |
35,075,251 |
RGD:6480464 |
CTD |
quercitrin
|
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
decreases activity |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
decreases activity |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
rutin
|
| G |
Acly |
ATP citrate lyase |
|
decreases activity |
ISO |
10 |
89,420,934 |
89,471,398 |
RGD:6480464 |
CTD |
| G |
Ager |
advanced glycosylation end product-specific receptor |
|
multiple interactions |
ISO |
20 |
4,250,613 |
4,253,540 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
decreases localization |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
|
increases localization |
ISO |
2 |
190,333,978 |
190,391,015 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
affects expression |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
affects expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
affects cleavage |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cbr1 |
carbonyl reductase 1 |
|
multiple interactions |
ISO |
11 |
33,787,957 |
33,790,320 |
RGD:6480464 |
CTD |
| G |
Cbr1 |
carbonyl reductase 1 |
|
multiple interactions |
ISO |
11 |
33,787,957 |
33,790,320 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
decreases expression |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
decreases expression |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
decreases secretion |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Cxcl10 |
chemokine (C-X-C motif) ligand 10 |
|
multiple interactions |
ISO |
14 |
17,265,986 |
17,268,183 |
RGD:6480464 |
CTD |
| G |
Cxcl10 |
chemokine (C-X-C motif) ligand 10 |
|
decreases secretion |
ISO |
14 |
17,265,986 |
17,268,183 |
RGD:6480464 |
CTD |
| G |
Cxcl10 |
chemokine (C-X-C motif) ligand 10 |
|
decreases expression |
ISO |
14 |
17,265,986 |
17,268,183 |
RGD:6480464 |
CTD |
| G |
Cxcl10 |
chemokine (C-X-C motif) ligand 10 |
|
decreases expression |
ISO |
14 |
17,265,986 |
17,268,183 |
RGD:6480464 |
CTD |
| G |
Cxcl10 |
chemokine (C-X-C motif) ligand 10 |
|
decreases secretion |
ISO |
14 |
17,265,986 |
17,268,183 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases expression |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
decreases activity |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Gsr |
glutathione reductase |
|
decreases activity |
ISO |
16 |
62,255,562 |
62,298,458 |
RGD:6480464 |
CTD |
| G |
Gsr |
glutathione reductase |
|
multiple interactions |
EXP |
16 |
62,255,562 |
62,298,458 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Igf1r |
insulin-like growth factor 1 receptor |
|
multiple interactions |
ISO |
1 |
122,704,976 |
122,990,007 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Irs1 |
insulin receptor substrate 1 |
|
decreases expression |
ISO |
9 |
81,585,251 |
81,638,071 |
RGD:6480464 |
CTD |
| G |
Irs1 |
insulin receptor substrate 1 |
|
multiple interactions |
ISO |
9 |
81,585,251 |
81,638,071 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
decreases expression |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
multiple interactions |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
decreases phosphorylation |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
decreases phosphorylation |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
decreases expression |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Pnpla3 |
patatin-like phospholipase domain containing 3 |
|
decreases expression |
ISO |
7 |
122,152,092 |
122,171,994 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Tgfa |
transforming growth factor alpha |
|
multiple interactions |
ISO |
4 |
120,355,649 |
120,437,772 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
multiple interactions |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
decreases expression |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
scutellarein
|
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
decreases activity |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
affects metabolic processing |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
affects metabolic processing |
ISO |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
decreases activity |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
affects metabolic processing |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
multiple interactions |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
scutellarin
|
| G |
App |
amyloid beta (A4) precursor protein |
|
multiple interactions |
EXP |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
multiple interactions |
EXP |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
decreases expression |
EXP |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
decreases expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
|
increases expression |
EXP |
4 |
6,158,847 |
6,179,441 |
RGD:6480464 |
CTD |
| G |
Pla2g2a |
phospholipase A2, group IIA (platelets, synovial fluid) |
|
affects activity |
ISO |
5 |
157,654,786 |
157,657,360 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
decreases expression |
EXP |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
Term paths to the root
| Path 1 |
CHEBI ontology |
492574 |
 |
chemical entity |
492574 |
 |
molecular entity |
475835 |
 |
polyatomic entity |
442085 |
 |
heteroatomic molecular entity |
376467 |
 |
hydroxides |
224546 |
 |
organic hydroxy compound |
104807 |
 |
hydroxyflavone |
5320 |
 |
tetrahydroxyflavone |
612 |
 |
3',4',5,6-tetrahydroxy-3,7-dimethoxyflavone |
0 |
 |
3',4',5,7-tetrahydroxy-3-methoxyflavone |
0 |
 |
3'-O-methyltricetin |
0 |
 |
6-hydroxyluteolin 7-O-laminaribioside |
0 |
 |
8-lavandulylkaempferol |
0 |
 |
avicularin |
0 |
 |
dorsilurin G |
0 |
 |
fisetin + |
51 |
 |
isoorientin + |
6 |
 |
isoorientin 2''-O-rhamnoside |
0 |
 |
isorhamnetin + |
12 |
 |
isoscutellarein + |
0 |
 |
isoscutellarein glycoside |
0 |
 |
kaempferol + |
237 |
 |
lucenin-2 |
0 |
 |
luteolin + |
187 |
 |
myricitrin-5-methyl ether |
0 |
 |
orientin |
0 |
 |
pedalitin |
0 |
 |
quercetin 3-O-beta-D-glucoside |
42 |
 |
quercetin 3-sulfate |
0 |
 |
quercetin 7-O-beta-D-glucoside |
0 |
 |
quercitrin |
2 |
 |
rutin |
66 |
 |
scutellarein + |
15 |
 |
syringetin |
0 |
 |
tamarixetin |
0 |
 |
| Path 2 |
CHEBI ontology |
492574 |
 |
subatomic particle |
491537 |
 |
composite particle |
491537 |
 |
hadron |
491537 |
 |
baryon |
491537 |
 |
nucleon |
491537 |
 |
atomic nucleus |
491537 |
 |
atom |
491537 |
 |
main group element atom |
461203 |
 |
p-block element atom |
458699 |
 |
carbon group element atom |
410677 |
 |
carbon atom |
407233 |
 |
organic molecular entity |
407226 |
 |
organic molecule |
359465 |
 |
organic cyclic compound |
298342 |
 |
organic heterocyclic compound |
154273 |
 |
oxacycle |
53252 |
 |
benzopyran |
18501 |
 |
| 1-benzopyran |
17612 |
 |
flavonoid |
7847 |
 |
flavones |
5352 |
 |
hydroxyflavone |
5320 |
 |
tetrahydroxyflavone |
612 |
 |
3',4',5,6-tetrahydroxy-3,7-dimethoxyflavone |
0 |
 |
3',4',5,7-tetrahydroxy-3-methoxyflavone |
0 |
 |
3'-O-methyltricetin |
0 |
 |
6-hydroxyluteolin 7-O-laminaribioside |
0 |
 |
8-lavandulylkaempferol |
0 |
 |
avicularin |
0 |
 |
dorsilurin G |
0 |
 |
fisetin + |
51 |
 |
isoorientin + |
6 |
 |
isoorientin 2''-O-rhamnoside |
0 |
 |
isorhamnetin + |
12 |
 |
isoscutellarein + |
0 |
 |
isoscutellarein glycoside |
0 |
 |
kaempferol + |
237 |
 |
lucenin-2 |
0 |
 |
luteolin + |
187 |
 |
myricitrin-5-methyl ether |
0 |
 |
orientin |
0 |
 |
pedalitin |
0 |
 |
quercetin 3-O-beta-D-glucoside |
42 |
 |
quercetin 3-sulfate |
0 |
 |
quercetin 7-O-beta-D-glucoside |
0 |
 |
quercitrin |
2 |
 |
rutin |
66 |
 |
scutellarein + |
15 |
 |
syringetin |
0 |
 |
tamarixetin |
0 |
 |
| |
|